Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Average Recommendation of “Moderate Buy” by Analysts

Posted by Brian Himes on May 24th, 2026

Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the eight analysts that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $15.1667.

Several research firms have recently weighed in on AMRX. UBS Group began coverage on shares of Amneal Pharmaceuticals in a research report on Friday, April 17th. They set a “buy” rating and a $19.00 price objective on the stock. Barclays raised their price objective on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research report on Wednesday. Truist Financial raised their price objective on shares of Amneal Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Zacks Research cut shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. Finally, Weiss Ratings upgraded shares of Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday, May 11th.

Read Our Latest Report on AMRX

Insider Activity at Amneal Pharmaceuticals

In related news, Director Deborah M. Autor sold 34,819 shares of the stock in a transaction on Monday, May 11th. The shares were sold at an average price of $12.94, for a total transaction of $450,557.86. Following the transaction, the director owned 93,660 shares of the company’s stock, valued at approximately $1,211,960.40. This trade represents a 27.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 17.30% of the company’s stock.

Hedge Funds Weigh In On Amneal Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the business. Bank of America Corp DE grew its holdings in shares of Amneal Pharmaceuticals by 50.0% during the 1st quarter. Bank of America Corp DE now owns 676,795 shares of the company’s stock valued at $8,413,000 after purchasing an additional 225,637 shares during the last quarter. Arkadios Wealth Advisors bought a new position in shares of Amneal Pharmaceuticals during the 1st quarter valued at $4,165,000. California State Teachers Retirement System grew its holdings in shares of Amneal Pharmaceuticals by 37.6% during the 1st quarter. California State Teachers Retirement System now owns 207,239 shares of the company’s stock valued at $2,576,000 after purchasing an additional 56,588 shares during the last quarter. Royal Bank of Canada grew its holdings in shares of Amneal Pharmaceuticals by 33.7% during the 1st quarter. Royal Bank of Canada now owns 12,646 shares of the company’s stock valued at $157,000 after purchasing an additional 3,191 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of Amneal Pharmaceuticals by 10.5% during the 1st quarter. The Manufacturers Life Insurance Company now owns 88,007 shares of the company’s stock valued at $1,094,000 after purchasing an additional 8,347 shares during the last quarter. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Stock Performance

Amneal Pharmaceuticals stock opened at $12.42 on Friday. The firm’s fifty day moving average price is $12.55 and its 200-day moving average price is $12.87. The stock has a market cap of $3.96 billion, a P/E ratio of 32.69 and a beta of 1.32. Amneal Pharmaceuticals has a fifty-two week low of $7.02 and a fifty-two week high of $15.42.

Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.27 earnings per share for the quarter. The firm had revenue of $722.52 million for the quarter. Amneal Pharmaceuticals had a net margin of 4.01% and a negative return on equity of 313.96%. On average, analysts predict that Amneal Pharmaceuticals will post 0.92 earnings per share for the current year.

Amneal Pharmaceuticals Company Profile

(Get Free Report)

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.